BioSpace News Archive

Battelle representatives are participating this week in the TERENO NEON Carbon Workshop 2019 in Düren, Germany, emphasizing the organization’s commitment to environmental research infrastructure (RI), data sharing and interoperability, worldwide research collaboration and building the next generation of researchers.

The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, has added Innovation and Value Initiative (IVI) to its Strategic Alliance Partnership (SAP) program.

Medal Recognizes Organizations That Reflect Company’s Commitment to Expanding Access to Care for People in Need

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) today announced its interim financial results for the second quarter ended May 31, 2019.

PHAR LLC (Los Angeles, CA and Boston, MA), a boutique health care consultancy dedicated to the practice of health economics and outcomes research, announces the appointment of Mallik Greene, BPharm, PhD, DBA to the position of Vice President for Health Economics and Outcomes Research (mgreene@pharllc.com).

Novocure announced the U.S Centers for Medicare & Medicaid Services has established a 2019 monthly fee schedule amount for Optune.

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has completed enrollment in its phase 3 trial evaluating arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS) ahead of schedule.

Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).

NuCana plc (NASDAQ: NCNA) a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, today announced that the first patients have been dosed in the Phase I study of NUC-7738.

First Biosimilar Avastin® and Herceptin® Products to Launch in the United States